CARsgen Therapeutics Holdings Limited

SEHK:2171 Stock Report

Market Cap: HK$5.0b

CARsgen Therapeutics Holdings Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Zonghai Li

Chief executive officer

CN¥2.1m

Total compensation

CEO salary percentage50.2%
CEO tenure3.8yrs
CEO ownershipn/a
Management average tenure3.3yrs
Board average tenure4.3yrs

Recent management updates

Recent updates

Is CARsgen Therapeutics Holdings (HKG:2171) Weighed On By Its Debt Load?

Dec 04
Is CARsgen Therapeutics Holdings (HKG:2171) Weighed On By Its Debt Load?

Is CARsgen Therapeutics Holdings (HKG:2171) Using Debt Sensibly?

Aug 31
Is CARsgen Therapeutics Holdings (HKG:2171) Using Debt Sensibly?

CARsgen Therapeutics Holdings (HKG:2171) Is In A Good Position To Deliver On Growth Plans

Jan 23
CARsgen Therapeutics Holdings (HKG:2171) Is In A Good Position To Deliver On Growth Plans

Companies Like CARsgen Therapeutics Holdings (HKG:2171) Are In A Position To Invest In Growth

Sep 05
Companies Like CARsgen Therapeutics Holdings (HKG:2171) Are In A Position To Invest In Growth

CEO Compensation Analysis

How has Zonghai Li's remuneration changed compared to CARsgen Therapeutics Holdings's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024n/an/a

-CN¥695m

Mar 31 2024n/an/a

-CN¥721m

Dec 31 2023CN¥2mCN¥1m

-CN¥748m

Sep 30 2023n/an/a

-CN¥834m

Jun 30 2023n/an/a

-CN¥920m

Mar 31 2023n/an/a

-CN¥906m

Dec 31 2022CN¥2mCN¥1m

-CN¥892m

Compensation vs Market: Zonghai's total compensation ($USD285.55K) is below average for companies of similar size in the Hong Kong market ($USD479.13K).

Compensation vs Earnings: Zonghai's compensation has increased whilst the company is unprofitable.


CEO

Zonghai Li (50 yo)

3.8yrs

Tenure

CN¥2,084,000

Compensation

Dr. Zonghai Li M.D., Ph D., is Co-Founder of CARsgen Therapeutics Holdings Limited and serves as its Chief Executive Officer and Chief Scientific Officer since February 2021 & Chairman of the Board. He ser...


Leadership Team

NamePositionTenureCompensationOwnership
Zonghai Li
Co-Founder3.8yrsCN¥2.08mno data
Huamao Wang
Co-Founder3.8yrsCN¥2.11mno data
Hua Jiang
Executive Director2.3yrsCN¥1.39mno data
Hong Ma
Senior Vice President of Clinical Developmentno datano datano data
Leigh Hsu
Senior Vice President of Business Developmentno datano datano data
Raffaele Baffa
Chief Medical Officer2.7yrsno datano data
Sylvie Peltier
Senior Vice President of Global Regulatory Affairs2.2yrsno datano data
Wing Yat Lui
Company Secretary3.8yrsno datano data

3.3yrs

Average Tenure

51yo

Average Age

Experienced Management: 2171's management team is considered experienced (3.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Zonghai Li
Co-Founder6.8yrsCN¥2.08mno data
Huamao Wang
Co-Founder6.3yrsCN¥2.11mno data
Hua Jiang
Executive Director2.3yrsCN¥1.39mno data
Ronggang Xie
Non-Executive Director4.3yrsno datano data
Xiangke Zhao
Independent Non-Executive Director1.4yrsCN¥80.00kno data
Bingsen Guo
Non-Executive Director6.3yrsno data1.62%
HK$ 80.3m
Guangmei Yan
Independent Non-Executive Director3.5yrsCN¥222.00kno data
Huaqing Guo
Non-Executive Director4.3yrsno data0.38%
HK$ 18.7m
Wen Zhou
Independent Non-Executive Directorless than a yearno datano data

4.3yrs

Average Tenure

47yo

Average Age

Experienced Board: 2171's board of directors are considered experienced (4.3 years average tenure).


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/31 21:23
End of Day Share Price 2024/12/31 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

CARsgen Therapeutics Holdings Limited is covered by 2 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Xiao Wei LinEverbright Securities Co. Ltd.
Ziyi ChenGoldman Sachs